BioNTech SE Reports Q3 2025 Results

Ticker: BNTX · Form: 6-K · Filed: 2025-11-03T00:00:00.000Z

Sentiment: neutral

Topics: earnings, financial-results, corporate-update

TL;DR

BioNTech dropped Q3 earnings report Nov 3rd.

AI Summary

BioNTech SE announced its third quarter 2025 financial results and corporate update on November 3, 2025. The company is a German biotechnology firm headquartered in Mainz.

Why It Matters

This filing provides investors with the latest financial performance and strategic updates from BioNTech SE, a key player in the biotechnology sector.

Risk Assessment

Risk Level: low — This is a routine financial results filing with no immediate material events indicated.

Key Players & Entities

FAQ

What is the filing type and submission date?

This is a Form 6-K filed on November 3, 2025.

What is the company's full name and headquarters?

The company's full name is BioNTech SE, and it is headquartered in Mainz, Germany.

What is the purpose of this Form 6-K?

This Form 6-K is a report of a foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, including a press release announcing third quarter 2025 financial results and corporate update.

Does BioNTech file annual reports under Form 20-F or 40-F?

BioNTech SE indicates it files annual reports under Form 20-F.

What is BioNTech's SIC code?

BioNTech's Standard Industrial Classification (SIC) code is 2836, for Biological Products (No Diagnostic Substances).

From the Filing

0001776985-25-000064.txt : 20251103 0001776985-25-000064.hdr.sgml : 20251103 20251103064951 ACCESSION NUMBER: 0001776985-25-000064 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 29 CONFORMED PERIOD OF REPORT: 20251103 FILED AS OF DATE: 20251103 DATE AS OF CHANGE: 20251103 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BioNTech SE CENTRAL INDEX KEY: 0001776985 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: 2M FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39081 FILM NUMBER: 251442050 BUSINESS ADDRESS: STREET 1: AN DER GOLDGRUBE 12 CITY: MAINZ STATE: 2M ZIP: 55131 BUSINESS PHONE: 0049613190840 MAIL ADDRESS: STREET 1: AN DER GOLDGRUBE 12 CITY: MAINZ STATE: 2M ZIP: 55131 6-K 1 form6-kq32025earningsprear.htm 6-K Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF NOVEMBER 2025 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20‑F or Form 40‑F: Form 20‑F ☒ Form 40‑F ☐ Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(1): ☐ Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(7): ☐ DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K On November 3, 2025, BioNTech SE (the “Company”) issued a press release announcing its third quarter 2025 financial results and corporate update and details of a conference call to be held at 8:00 am EST on November 3, 2025 to discuss the results. The press release and the conference call presentation are attached as Exhibits 99.1 and 99.2, respectively, and incorporated by reference herein. The information contained in Exhibits 99.1 and 99.2 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, unless expressly set forth by specific reference in such a filing. SIGNATURE Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BioNTech SE By: /s/ Ramón Zapata-Gomez By: /s/ Dr. Sierk Poetting Name: Ramón Zapata-Gomez Name: Dr. Sierk Poetting Title: Chief Financial Officer Title: Chief Operating Officer Date: November 3, 2025 EXHIBIT INDEX Exhibit Description of Exhibit 99.1 BioNTech Announces Third Quarter 2025 Financial Results and Corporate Update 99.2 Third Quarter 2025: Corporate Update and Financial Results EX-99.1 2 a99120251103_bntxq32025pre.htm EX-99.1 Document Exhibit 99.1 BioNTech Announces Third Quarter 2025 Financ ial Results and Corporate Update • Continued clinical execution of oncology strategy with focus on two pan-tumor programs, including combination approaches to address the full continuum of cancer from early to late disease stages • Demonstrated encouraging anti-tumor activity and manageable safety profile of pumitamig (BNT327/BMS986545), a bispecific antibody candidate targeting PD-L1 1 and VEGF-A , in first disclosed interim data from global Phase 2 trial in extensive-stage small cell lung cancer • Plan to initiate additional pivotal trials for pumitamig in first-line microsatellite stable c

View on Read The Filing